ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

Core Insights - ARS Pharmaceuticals, Inc. will host a conference call and webcast on November 10, 2025, to discuss its Q3 2025 financial results and business highlights [1] - The company is focused on empowering at-risk patients and caregivers to protect against allergic reactions that could lead to anaphylaxis [3] Company Overview - ARS Pharmaceuticals is commercializing neffy (EURneffy in the EU), an epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis, in patients aged 4 years and older who weigh at least 15 kg in the U.S. and for patients weighing at least 30 kg in the EU [3] - The product is indicated for allergic reactions due to insect stings or bites, foods, medicinal products, and other allergens, as well as idiopathic or exercise-induced anaphylaxis [3]